Gene expression dosage as a driver of cellular and physiological traits

This project aims to characterize gene dosage-to-function relationships in human blood cells using genetic data and CRISPR techniques to enhance understanding of disease mechanisms and genomic medicine.

Subsidie
€ 1.993.059
2022

Projectdetails

Introduction

The expression dosage of a gene is a fundamental determinant of its downstream function at the cellular and organismal level. Its genetic or environmental perturbations are a driving force of most common and rare diseases in humans. However, we have limited understanding of the specific shape of dosage-to-function curves for human genes, what factors and mechanisms drive their variation across genes, phenotypes, and cellular contexts, and how this contributes to the functional architecture of human traits.

Project Overview

This project addresses these questions using large human genetic data sets and cutting-edge experimental approaches. Using blood cell traits as our study system, we will characterize the relationship between gene dosage and cellular and physiological function on an unprecedented scale and depth. This addresses fundamental questions in systems biology and produces insights that can also benefit genomic medicine and drug development.

Work Packages

The Work Packages of this study will:

  1. Establish the dosage-to-function relationship for hundreds of human genes, associating genetically driven gene dosage to blood cell traits in large human genetic data, and by an innovative CRISPR-based experimental approach that maps gene dosage changes to multiple cellular phenotypes.
  2. Elucidate how the dosage-to-cellular-function relationships differ between cellular states, and use single-cell RNA sequencing to analyze how regulatory networks mediate context-specific dosage-to-function effects.
  3. Characterize upstream genomic and environmental regulators of gene dosage.

Expected Outcomes

This project will build the first comprehensive, generalizable picture of gene dosage-to-function relationships in humans. Our analysis will link these insights to the functional architecture of human traits, providing unique generalizable insights into how disruption of gene dosage and regulatory networks underlies human traits at the cellular and physiological level.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.993.059
Totale projectbegroting€ 1.993.059

Tijdlijn

Startdatum1-7-2022
Einddatum30-6-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • KUNGLIGA TEKNISKA HOEGSKOLANpenvoerder

Land(en)

Sweden

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Regulation of gene dosage on the mouse X chromosome

REGULADOSIX aims to uncover the evolutionary and functional mechanisms of X-chromosome inactivation in mammals by studying gene dosage compensation during mouse embryogenesis.

€ 1.954.154
ERC Consolid...

Discover the physiological and developmental functions of X chromosome dosage using new genetic and system models

This project aims to uncover the mechanisms of X monosomy lethality and the role of sex chromosome dosage in development using advanced fly genetics and novel insect models.

€ 1.983.769
ERC Advanced...

Deep genetics to study and uncover ‘hidden’ biology

DeepGenetics aims to enhance understanding of genetic regulation in human cells by linking cellular phenotypes to protein domains and amino acids, revealing hidden biological processes.

€ 2.451.625
ERC Consolid...

Systematically Dissecting the Regulatory Logic of Chromatin Modifications

This project aims to systematically investigate the functional impact of chromatin modifications on gene expression using a novel editing platform to enhance precision medicine and understand epigenomic profiles.

€ 1.999.565
ERC Starting...

Shedding light on three-dimensional gene regulation

This project aims to elucidate gene expression regulation during differentiation using an ultra-fast optogenetic system and high-resolution genomic tools to study 3D chromatin interactions.

€ 1.500.000